Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 10, 2015, Pages 6575-6580

  Rigatto, Maria Helena ^a   Vieira, Fabiane J ^b   Antochevis, Laura C ^b   Behle, Tainá F ^c   Lopes, Natane T ^b   Zavasckic, Alexandre P ^b,c  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; CARBAPENEM; POLYMYXIN B; ANTIINFECTIVE AGENT; DRUG COMBINATION;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; AGED; APACHE; ARTICLE; BROTH DILUTION; COHORT ANALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; FEMALE; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; PROPENSITY SCORE; PSEUDOMONAS INFECTION; ACINETOBACTER INFECTIONS; CRITICAL ILLNESS; DRUG COMBINATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDY; VERY ELDERLY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; CRITICAL ILLNESS; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES;

EID: 84942939969     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00494-15     Document Type: Article

References (23)

1. Zavascki AP, Bulitta JB, Landersdorfer CB. 2013. Combination therapy for carbapenem-resistant Gram-negative bacteria. Expert Rev Anti Infect Ther 11:1333-1353. http://dx.doi.org/10.1586/14787210.2013.845523.
2. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Lijequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Webet JT, Monnet DL. 2012. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18:268-281. http://dx.doi.org/10.1111/j.1469-0691.2011.03570.x.
3. Spellberg B, Bonomo RA. 2014. The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med 42:1289-1291. http://dx.doi.org/10.1097/CCM.0000000000000181.
4. Kollef MH, Chastre J, Fagon JY, François B, Niederman MS, Rello J, Torres A, Vincent JL, Wunderink RG, Go KW, Rehm C. 2014. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit Care Med 42:2178-2187. http://dx.doi.org/10.1097/CCM.0000000000000510.
5. Nation RL, Velkov T, Li J. 2014. Colistin and polymyxin B: peas in a pod, or chalk and cheese? Clin Infect Dis 59:88-94. http://dx.doi.org/10.1093/cid/ciu213.
6. Zavascki AP, Goldani LZ, Li J, Nation RL. 2007. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60:1206-1215. http://dx.doi.org/10.1093/jac/dkm357.
7. Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacçonelli E, Theuretzbacher U, Mussini C, Leibovivi L. 2014. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:2305-2309. http://dx.doi.org/10.1093/jac/dku168.
8. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M. 2012. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55:943-950. http://dx.doi.org/10.1093/cid/cis588.
9. Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A. 2014. Carbapenemaseproducing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58:2322-2328. http://dx.doi.org/10.1128/AAC.02166-13.
10. Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. 2006. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gramnegative bacterial infections. Clin Microbiol Infect 12:1227-1230. http://dx.doi.org/10.1111/j.1469-0691.2006.01559.x.
11. Sandri AM, Landersdorfer CB, Jacob J, Boniatti MM, Dalarosa MG, Falci DR, Behle TF, Saitovitch D, Wang J, Forrest A, Nation RL, Zavascki AP, Li J. 2013. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:524-531. http://dx.doi.org/10.1093/cid/cit334.
12. Horan TC, Andrus M, Dudeck MA. 2008. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36:309-332. http://dx.doi.org/10.1016/j.ajic.2008.03.002.
13. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383. http://dx.doi.org/10.1016/0021-9681 (87) 90171-8.
14. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. 1985. APACHE II: a severity of disease classification system. Crit Care Med 13:818-829. http://dx.doi.org/10.1097/00003246-198510000-00009.
15. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement M100-S21. CLSI, Wayne, PA.
16. Bergen PJ, Bulman ZP, Saju S, Bulitta JB, Landersdorfer C, Forrest A, Li J, Nation RL, Tsuji BT. 2015. Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy 35:34-42. http://dx.doi.org/10.1002/phar.1537.
17. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. 2009. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142-150. http://dx.doi.org/10.1093/jac/dkp139.
18. Elias LS, Konzen D, Krebs JM, Zavascki AP. 2010. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65:2231-2237. http://dx.doi.org/10.1093/jac/dkq285.
19. Lat A, Clock SA, Wu F, Whittier S, Della-Latta P, Fauntleroy K, Jenkins SG, Saiman L, Kubin CJ. 2011. Comparison of polymyxin B, tigecycline, cefepime, and meropenem MICs for KPC-producing Klebsiella pneumoniae by broth microdilution, Vitek 2, and Etest. J Clin Microbiol 49:1795-1798. http://dx.doi.org/10.1128/JCM.02534-10.
20. Girardello R, Bispo PJ, Yamanaka TM, Gales AC. 2012. Cation concentration variability of four distinct Mueller-Hinton agar brands influences polymyxin B susceptibility results. J Clin Microbiol 50:2414-2418. http://dx.doi.org/10.1128/JCM.06686-11.
21. Lee SY, Shin JH, Lee K, Joo MY, Park KH, Shin MG, Suh SP, Ryang DW, Kim SH. 2013. Comparison of the Vitek 2, MicroScan, and Etest methods with the agar dilution method in assessing colistin susceptibility of bloodstream isolates of Acinetobacter species from a Korean university hospital. J Clin Microbiol 51:1924-1926. http://dx.doi.org/10.1128/JCM.00427-13.
22. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M, Malacarne P, Petrosillo N, Galdieri N, Mocavero P, Corcione A, Viscoli C, Zarrilli R, Gallo C, Utili R. 2013. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57:349-358. http://dx.doi.org/10.1093/cid/cit253.
23. Aydemir H, Akduman D, Piskin N, Comert F, Horuz E, Terzi A, Kokturk F, Ornek T, Celebi G. 2013. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141:1214-1222. http://dx.doi.org/10.1017/S095026881200194X.